This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Biotech Stock Roundup: NVAX Up on Updates, ALXO Gains on Study Data & More
by Zacks Equity Research
Regulatory and pipeline updates from Novavax (NVAX) and ALX Oncology Holdings (ALXO) are in focus in the biotech sector.
Moderna (MRNA) to Advance COVID/Flu Combo Jab to Late-Stage Study
by Zacks Equity Research
Moderna's (MRNA) intends to start the late-stage study on its COVID-19-influenza combination vaccine candidate before year-end. A commercial launch is expected in 2025.
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $104.26, marking a +1.14% move from the previous day.
Novavax (NVAX) Up 8% on FDA Nod for Updated COVID Booster Jab
by Zacks Equity Research
Novavax's (NVAX) updated COVID vaccine is authorized under emergency use for individuals aged 12 years and older. It is currently the only non-mRNA COVID vaccine available in the country.
Alexandria (ARE) Expedites Delivery of Moderna's New HQ
by Zacks Equity Research
Alexandria (ARE) to hand over the new global headquarters and core R&D operations center to Moderna in November 2023. ARE will benefit from the project's incremental annual net operating income.
The Zacks Analyst Blog Highlights Intel, Anheuser-Busch InBev, HCA Healthcare, Moderna and DuPont de Nemours
by Zacks Equity Research
Intel, Anheuser-Busch InBev, HCA Healthcare, Moderna and DuPont de Nemours are included in this Analyst Blog.
Top Stock Reports for Intel, Anheuser-Busch & HCA Healthcare
by Sheraz Mian
Today's Research Daily features new research reports on 12 major stocks, including Intel Corporation (INTC), Anheuser-Busch InBev SA/NV (BUD) and HCA Healthcare, Inc. (HCA).
Is it Time to Buy Pfizer, Moderna, or AstraZeneca's Stock?
by Shaun Pruitt
Despite slowing COVID-19 vaccine sales these healthcare titans are trading at more reasonable valuations with a lot of the risk-to-reward being priced into their stocks considering their earnings potential.
Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $100.27, marking a +0.83% move from the previous day.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Moderna (MRNA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $99.99, moving -0.24% from the previous trading session.
Biotech Stock Roundup: GSK's Drug Approval, MRNA's Vaccine News, PTCT & SPRY Down
by Zacks Equity Research
Regulatory updates from GSK and Moderna (MRNA) are in focus in the biotech sector.
Moderna (MRNA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $114.59 in the latest trading session, marking a +1.58% move from the prior day.
Moderna (MRNA) Receives CHMP Nod for Updated COVID Vaccine
by Zacks Equity Research
Clinical data from studies on Moderna's (MRNA) updated COVID vaccine shows improved antibody responses against multiple circulating variants, including BA.2.86, EG.5 and FL.1.5.1 variants.
Pharma Stock Roundup: FDA Nod to Updated PFE, MRNA COVID Jabs, & More
by Kinjel Shah
The FDA authorizes Pfizer (PFE) and Moderna's (MRNA) updated mRNA-based COVID-19 vaccines. Novo Nordisk (NVO) conducts a two-for-one split of its shares and ADRs.
Company News for Sep 15, 2023
by Zacks Equity Research
Companies in The News Are: HPQ, BRK.B, SMTC, MRNA, CWK
Moderna (MRNA) Posts '28 Biz View, Up 3% on Upbeat Flu Jab Data
by Zacks Equity Research
Moderna's (MRNA) reformulated influenza vaccine candidate meets the primary endpoint in a late-stage study. It expects to launch up to 15 new products in the next five years.
Biotech Stock Roundup: MRNAs Pipeline News, RCKT, BCYC Rally on Study Updates
by Zacks Equity Research
Pipeline and regulatory updates from Moderna (MRNA) and Rocket Pharmaceuticals (RCKT) are in focus in the biotech sector.
Moderna (MRNA) Surges 3.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Moderna (MRNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna and Novavax
by Zacks Equity Research
Pfizer, BioNTech, Moderna and Novavax are included in this Analyst Blog.
Moderna (MRNA), Immatics Ink Deal to Develop New Cancer Therapies
by Zacks Equity Research
The deal will combine Moderna (MRNA) and Immatics' (IMTX) proprietary platforms to develop innovative immunotherapies for cancer.
FDA Approves Pfizer & Moderna's New COVID Booster Vaccines
by Kinjel Shah
Pfizer (PFE)/ BioNTech (BNTX), and Moderna's (MRNA) updated mRNA vaccines are now approved for individuals 12 years of age and older and are authorized under emergency use for individuals 6 months through 11 years of age.
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $107.64, marking a -0.66% move from the previous day.
Biotech Stock Roundup: MRNA's Vaccine Update, AMGN & HZNP Clear FTC Lawsuit & More
by Zacks Equity Research
Pipeline and regulatory updates from (MRNA) and Amgen (AMGN) are in focus in the biotech sector.
Moderna (MRNA) Updated COVID Jab Effective Against Pirola Variant
by Zacks Equity Research
Clinical study data shows Moderna's (MRNA) updated COVID-19 vaccine generates a robust immune response against newer circulating variants, including Pirola and Eris.